May 15, 2014 Printable agenda
8:00 am - 9:00 am	Breakfast and Registration
9:00 am - 9:05 am	Opening Remarks from the Chair Andrew Ward, Pharmaceuticals Correspondent, Financial Times
9:05 am - 9:30 am	View from the Top Sandra Peterson, Group Worldwide Chairman, Johnson & Johnson
9:30 am - 10:30 am	US Healthcare Reform: The Next Chapter Karen Ignagni, President and CEO, America's Health Insurance Plans (AHIP) Stephen Rusckowski, President and CEO, Quest Diagnostics Lori Reilly, Vice-President for Policy and Research, Pharmaceutical Research and Manufacturers of America (PhRMA) The reforms initiated by the Affordable Care Act (ACA) are gaining traction. Despite initial challenges, enrolment in the new health insurance exchanges is underway. Payers, providers and life insurance companies are experimenting with new pay-for-performance measures, and established and emerging players are realizing the potential for, and slowly building new businesses focused on bringing healthcare close to patient. In so doing, many of the stakeholders in the healthcare business are recalibrating relationships across the healthcare value chain. 2014 is a critical year in the reform process as the individual mandate kicks-in. As we cross this new threshold, what has been the impact of reform to date and the key learnings?  • How is reform impacting the ‘ecosystem’ of the healthcare and life science industry and how are stakeholder strategies evolving to take advantage of reform?  • How is reform reshaping market access? • How are the reforms changing the way patients consume healthcare? Are they seeing improvements in their care and access?
10:30 am - 11:00 am	Networking Coffee Break
11:00 am - 11:25 am	Keynote Address Esther Dyson, Chairman, EDventure Holdings
11:25 am - 12:25 pm	Healthcare Everywhere: Embracing the Mobile Health Opportunity Moderator: Harry Greenspun MD, Senior Advisor for Health Care Transformation & Technology, Deloitte Center for Health Solutions Keynote Speaker: Freda C.Lewis-Hall MD, Executive Vice President, Chief Medical Officer, Pfizer Tom Gentile, President & CEO, Healthcare Systems, GE Healthcare Kerry McDermott, Senior Director, Healthcare Technology Policy, West Health Mike Ross, Area Vice President, Healthcare, Verizon Enterprise Solutions Mobile healthcare-particularly when combined with other smart technologies including the cloud, social networking and the power of big data, has the potential to transform healthcare through reduced costs, extended access, changed behaviors and improved outcomes. While the reported benefits of mHealth are well known however, many have been unable to capitalize on the potential and develop mobile strategies which move beyond marketing and applications to solutions and partnerships which can make a quantum impact across the continuum of care. How can the potential of mobile health be harnessed? • What are the impediments to growth and how can they be addressed? How is the legal, regulatory and reimbursement regime evolving to support the expansion of mobile health and to address concerns regarding privacy and security? • What are the business models for mHealth which will provide solid returns for those who take the investment risk?  • How are key issues including interoperability being resolved to enable actionable knowledge and insights from accrued mobile data, and to achieve scalable benefits through wider collaboration across the health care spectrum?
12:25 am - 12:45 pm	CEO Insights Deborah Keller, Executive Vice President and Group President, R&D Laboratories, Covance
12:45 pm - 2:15 pm	Luncheon - Sponsor: Cigna David Cordani, President and CEO, Cigna
2:15 pm - 3:15 pm	Value-Based Contracting and Payments - Rising to the Challenge Keynote Speaker: Charles W. Sorenson MD, President and CEO, Intermountain Healthcare Jack Bailey, Senior Vice President, Policy, Payers and Vaccines, GlaxoSmithKline Terry Hisey, Vice Chairman, US Life Sciences Leader, Deloitte David Wennberg MD, CEO, Northern New England Accountable Care Collaborative (NNEACC) Universality of access may be making headlines in the on-going debate on US healthcare reform but potentially the largest impact will come from the measures aimed at tackling the escalating costs and improving the quality of care. From Accountable Care Organizations and CER in the US to the UK’s value-based pricing to Canada’s multi agency, multi-level networks, ’pay-for-performance' reforms which price healthcare products and services based on the value and quality, rather than volume they accrue to patients and the healthcare systems are making inroads and transforming healthcare around the globe. The goals of the new value system are clear but many uncertainties remain. • What is the evidence to date from the ACO pilots and value based pricing models for life science currently in place? What are the prospects the new structures leading to a sustainable and notable disruption in the quality and cost of care?  • Will the benefits outweigh the costs and risks, and is the infrastructure ready to underpin the system?  • What are the value metrics and incentive structures, and are current methodologies fair? Who decides?  • How are new pay-for-performance measures impacting access for life science companies? How does the US experience compare to that in Europe and elsewhere?
3:15 pm - 3:40 pm	Networking Coffee Break
3:40 pm - 4:10 pm	CEO Insights Omar Ishrak PhD, Chairman and CEO, Medtronic
4:10 pm - 4:40 pm	Closing Keynote Robert Hariri MD, PhD, Co-Founder and Vice Chairman, Human Longevity, Inc.
4:40 pm - 4:45 pm	Closing Remarks from the Chair Andrew Ward, Pharmaceuticals Correspondent, Financial Times
4:45 pm - 5:45 pm	Cocktail Reception